These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 3753662)

  • 1. Potential roles for preclinical pharmacology in phase I clinical trials.
    Collins JM; Zaharko DS; Dedrick RL; Chabner BA
    Cancer Treat Rep; 1986 Jan; 70(1):73-80. PubMed ID: 3753662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics.
    Newell DR; Burtles SS; Fox BW; Jodrell DI; Connors TA
    Br J Cancer; 1999 Nov; 81(5):760-8. PubMed ID: 10555743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relation of preclinical toxicology to findings in early clinical trials.
    Grieshaber CK; Marsoni S
    Cancer Treat Rep; 1986 Jan; 70(1):65-72. PubMed ID: 3943115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trials of single agents in adult solid tumours: preclinical and clinical aspects.
    Dodion P; Kenis Y; Staquet M
    Drugs Exp Clin Res; 1986; 12(1-3):23-30. PubMed ID: 3732050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Phase I trials--clinical studies of antineoplastic agents].
    Takahashi H; Wakui A; Yokoyama M; Oikawa H; Yoshioka T; Matsuoka S
    Gan To Kagaku Ryoho; 1991 Jul; 18(9):1477-85. PubMed ID: 1854218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of preclinical toxicology studies for platinum anticancer drugs.
    Clark DL; Andrews PA; Smith DD; DeGeorge JJ; Justice RL; Beitz JG
    Clin Cancer Res; 1999 May; 5(5):1161-7. PubMed ID: 10353752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Animal toxicology for early clinical trials with anticancer agents.
    Rozencweig M; Von Hoff DD; Staquet MJ; Schein PS; Penta JS; Goldin A; Muggia FM; Freireich EJ; DeVita VT
    Cancer Clin Trials; 1981; 4(1):21-8. PubMed ID: 6783332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
    Dees EC; Whitfield LR; Grove WR; Rummel S; Grochow LB; Donehower RC
    Clin Cancer Res; 2000 Oct; 6(10):3885-94. PubMed ID: 11051234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategy for the development of novel anticancer drugs.
    Saijo N; Tamura T; Nishio K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
    Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative prediction of drug toxicity in humans from toxicology in small and large animals.
    Goldsmith MA; Slavik M; Carter SK
    Cancer Res; 1975 May; 35(5):1354-64. PubMed ID: 804350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adequacies and inadequacies in assessing murine toxicity data with antineoplastic agents.
    Guarino AM; Rozencweig M; Kline I; Penta JS; Venditti JM; Lloyd HH; Holzworth DA; Muggia FM
    Cancer Res; 1979 Jun; 39(6 Pt 1):2204-10. PubMed ID: 445419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers.
    Bhargava P; Marshall JL; Dahut W; Rizvi N; Trocky N; Williams JI; Hait H; Song S; Holroyd KJ; Hawkins MJ
    Clin Cancer Res; 2001 Dec; 7(12):3912-9. PubMed ID: 11751482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus.
    Tijink BM; Buter J; de Bree R; Giaccone G; Lang MS; Staab A; Leemans CR; van Dongen GA
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6064-72. PubMed ID: 17062682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001.
    Cunningham C; Nemunaitis J
    Hum Gene Ther; 2001 Aug; 12(12):1594-6. PubMed ID: 11529249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose escalation trial designs based on a molecularly targeted endpoint.
    Hunsberger S; Rubinstein LV; Dancey J; Korn EL
    Stat Med; 2005 Jul; 24(14):2171-81. PubMed ID: 15909289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Phase I clinical trial design of anticancer agents--a Fibonacci and a modified Fibonacci sequence].
    Kusaba H; Tamura T
    Gan To Kagaku Ryoho; 2000 May; 27(5):775-8. PubMed ID: 10832451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.